Clinical Cancer Research

Table of Contents

May 15, 2015 • Volume 21 • Number 10

Highlights of This Issue 2193

SPECIAL FEATURES

CCR 20th Anniversary Commentary

2195  CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
       Susan E. Bates, Robert W. Robey, and Richard L. Piekaz

2198  CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
       Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

CCR Translations

2201  A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
       Yanping Xiao and Gordon J. Freeman
       See related article, p. 2359

2204  Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a ''String''
       Lisa M. Rimsza
       See related article, p. 2367

Molecular Pathways

2207  Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells
       Hiba Ahmad Zahreddine and Katherine L.B. Borden

CCR Focus

2212  Quit Early, Quit Often
       Susan E. Bates

2213  Lung Cancer in the Era of Precision Medicine
       Katerina Politi and Roy S. Herbst

2221  EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
       Gregory J. Riely and Helena A. Yu

2227  Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
       Ryoohe Katayama, Christine M. Lovly, and Alice T. Shaw

2236  Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
       David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch

2244  Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
       M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin

2256  Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
       Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger

Special Report

2263  Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care
       Edward Abrahams, Margaret Foti, and Marcia A. Kean

CANCER THERAPY: CLINICAL

2268  Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
       Shinichi Kageyama, Hiroaki Ikeda, Yoshihiro Miyahara, Naoko Imai, Mikiya Ishihara, Kanako Saito, Sahoko Sugino, Shugo Ueda, Takeshi Ishikawa, Satoshi Kokura, Hiroaki Naota, Koushi Ohishi, Taizo Shiraiishi, Naoki Inoue, Masahide Tanabe, Tomohide Kidokoro, Hirofumi Yoshioka, Daisuke Tomura, Ikuei Nukaya, Junichi Mineno, Kazutoh Takesako, Naoyuki Katayama, and Hiroshi Shiku

2278  Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

iv
Table of Contents

2289 Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

2297 The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, and Ferry A.L.M. Eskens

2305 Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dixon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, and Ritesh Rathore

2315 Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

2325 Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Ekeran, Joerg Kleeff, Bruno Sainz Jr, and Christopher Heeschen

2338 Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, and Donald Kufe

2348 Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Siddhar Vempati, Janna Minehatt, Matthew Witsin, Jun Qi, Andrei V. Kritsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong

BIOLOGY OF HUMAN TUMORS

2359 Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Murali Janakiram, Jordan M. Chinai, Susan Fineberg, András Fiser, Cristina Montagna, Ramadevi Medavarpulu, Ekaterina Castano, Hyungjun Jeon, Kim C. Ohnagbulam, Ruihu Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang
See related commentary, p. 2201

2367 Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
See related commentary, p. 2204

2379 Molecular Changes Associated with Acquired Resistance to Crizotinib in ROSI-Rearranged Non–Small Cell Lung Cancer
Alinah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

2388 Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Jasmin Wellbrock, Emily Latuske, Julian Köhler, Katharina Wagner, Hauke Stamm, Elker Vettorazzi, Gabi Vehwinkel, Marianne Klokov, Roswitha Uibeileisen, Patrick Ehm, Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jäcker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, and Walter Fiedler

CORRECTION

2412 Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.